In this article
Eli Lilly
on Thursday said its closely watched obesity pill helped patients maintain the majority of their weight loss after they switched directly from taking the company’s injection Zepbound and Novo Nordisk’s rival shot Wegovy in a late-stage trial.
The company also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for obesity. The FDA in November said it awarded a priority review voucher to that pill, which could expedite its review timeline to a few months.
The positive trial data suggest that the pill could be an effective treatment for patients to transition to if they want to preserve their weight loss but don’t want to take weekly injections long-term. Many people who stop those shots regain much of the weight they initially shed.
